首页> 外文期刊>Clinical Cancer Investigation Journal >Investigation of microsatellite instability BAT25 and BAT26 in breast cancer patients by conventional polymerase chain reaction
【24h】

Investigation of microsatellite instability BAT25 and BAT26 in breast cancer patients by conventional polymerase chain reaction

机译:常规聚合酶链反应研究乳腺癌患者微卫星不稳定性BAT25和BAT26

获取原文
           

摘要

Context: Breast cancer is the most common cancer among women worldwide, comprising 23% of the 1.1 million female cancers that newly diagnosed each year. Aims: The aim is to investigate the existence of microsatellite instability (MSI) in breast cancer of patients. Settings and Design: Fifty female patients with invasive ductal breast carcinoma collected. Inclusion criteria of patients include female patients with diagnostic feature of breast cancer and age range 26–42-year-old untreated with chemotherapy or hormonal therapy. Subjects and Methods: DNA had be extracted from frozen tissue samples of breast cancer. This protocol done according to the kit manufacture's manual of QIAamp DNA Mini Kit from Qiagen – USA. All samples tested for MSI by singleplex polymerase chain reactions (PCRs) using two microsatellite markers BAT25 and BAT26. PCR achieved in a final volume of 50 μl and after thermal cycles, gel visualization performed. Statistical Analysis Used: The significance of differences in proportions was analyzed using the Fisher's exact test with SPSS version 20 and values of P ≤ 0.001 considered statistically significant. Results: PCR demonstrating MSI in 13 (26%) of the 50 breast cancer sample. Eight (16%) of 50 breast cancer sample were BAT25 positive with a PCR product size of 124 bp, whereas 5 (10%) of 50 breast cancer sample were BAT26 positive with a PCR product size 121 bp. Conclusions: The result suggests strong evidence that MSI at the BAT25 and BAT26 and have involved in the pathogenesis of the great majority of breast cancers.
机译:背景:乳腺癌是全世界女性中最常见的癌症,占每年新诊断的110万女性癌症的23%。目的:目的是研究患者乳腺癌中微卫星不稳定性(MSI)的存在。设置与设计:收集五十名女性浸润性导管癌患者。患者的纳入标准包括具有乳腺癌诊断特征的女性患者,年龄在26-42岁之间,未经化学疗法或激素疗法治疗。研究对象和方法:从乳腺癌的冷冻组织样本中提取DNA。该协议是根据美国Qiagen的QIAamp DNA Mini Kit试剂盒制造商手册完成的。使用两个微卫星标记BAT25和BAT26,通过单重聚合酶链反应(PCR)测试所有样品的MSI。 PCR最终体积为50μl,热循环后,进行凝胶可视化。使用的统计分析:使用Fisher精确检验(SPSS版本20)分析比例差异的显着性,并且P≤0.001的值被认为具有统计学意义。结果:PCR证实了50个乳腺癌样品中的13个(26%)的MSI。 50个乳腺癌样本中有8个(16%)的BAT25阳性,PCR产物大小为124 bp,而50个乳腺癌样本中有5个(10%)的BAT26阳性,PCR产物大小为121 bp。结论:该结果表明强有力的证据表明,BAT25和BAT26的MSI参与了绝大多数乳腺癌的发病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号